RADNOR, PA / ACCESSWIRE / February 28, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (”Synergy” or the ”Company”) on behalf of purchasers of the Company’s securities between September 5, 2017 and November 14, 2017, inclusive (the ”Class Period”).

Deadline Reminder: Investors who purchased Synergy securities during the Class Period may, no later than April 10, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information, please visit https://www.ktmc.com/new-cases/synergy-pharmaceuticals-inc#join.

Synergy is a biopharmaceutical company focused on the development and commercialization of therapies to treat gastrointestinal disorders and diseases. On September 5, 2017, the Company issued a press release announcing that it had ”closed on a $300 million debt financing structured as senior secured loans from CRG LP, a healthcare-focused investment firm, and its lender syndicate” (the ”CRG Loan”). At that time, Synergy’s Chief Financial Officer represented to investors that the CRG Loan was ”non-dilutive financing.”

However, as detailed in the shareholder class action complaint, Synergy and certain of its executive officers failed to disclose that the CRG Loan was subject to various onerous terms and conditions, and made a series of false and misleading statements to investors about the CRG Loan, including: (i) its purported non-dilutive effect; (ii) its availability; and (iii) its sufficiency to fund the Company’s operations.

On November 9, 2017, Synergy filed a Form 10-Q with the SEC and disclosed the CRG Loan’s terms and conditions. Specifically, and as detailed in the complaint, ”the terms of the CRG Loan were dilutive to the outstanding equity interests of shareholders,” and the CRG Loan by itself could not and would not provide Synergy with sufficient financial flexibility or funding. Following this news, shares of the Company’s common stock declined over 8.4%, to close at $2.72 per share on November 10, 2017.

Subsequently, on November 13, 2017, the Company announced that it had priced an equity offering of common stock and warrants. Following this additional news, shares of the Company’s common stock continued to decline and closed as low as $1.89 per share on November 15, 2017.

Synergy shareholders may, no later than April 10, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.The firm represents investors, consumers, and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 489096

RADNOR, PA / ACCESSWIRE / February 28, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a class action lawsuit has been filed against GoPro, Inc. (NASDAQ: GPRO) (“GoPro” or the “Company”) on behalf of purchasers of the Company’s securities between August 4, 2017 and January 5, 2018, inclusive (the “Class Period”).

GoPro shareholders may, no later than March 12, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/gopro-inc-2018#join.

Shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 299 – 7706 or (610) 667 – 7706, or via e-mail at info@ktmc.com.

GoPro develops and sells mountable and wearable cameras and accessories.During the Class Period, GoPro’s product offerings included “Karma,” a premium remote-controlled drone that retailed for $799.

On November 1, 2017, GoPro held an earnings conference call with investors and financial analysts to discuss the Company’s financial results. During that call, GoPro’s Chief Executive Officer (“CEO”) represented to investors that “the consumer feedback to Karma specifically, actual owners of Karma has been quite good, and so we’re feeling really good about our prospects in the future there.”

The shareholder class action complaint alleges that, throughout the Class Period, GoPro and certain of its senior executive officers made false and misleading statements and/or failed to disclose that: (i) the market prospects for Karma were untenable due to margin challenges in an extremely competitive aerial market and a hostile regulatory environment in Europe and the United States; and (ii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

On January 8, 2018, GoPro disclosed, among other things: (i) that it was reducing its global workforce by approximately 20%; (ii) that, due to “margin challenges in an extremely competitive aerial market,” the Company would be exiting the aerial market after selling its remaining Karma inventory; and (iii) that the Company would incur an estimated $23 – 33 million in restructuring charges.

Following this news, shares of GoPro’s stock fell $0.96 per share, or over 12.7%, to close on January 8, 2018 at $6.56 per share, on heavy trading volume.

GoPro shareholders may, no later than March 12, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers, and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 491200

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Tesaro, Inc. (“Tesaro” or the “Company”) (NASDAQ: TSRO) and certain of its officers, on behalf of shareholders who purchased Tesaro securities during the period between March 14, 2016 and January 12, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/tsro.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with TESARO’s intravenous formulation of Varubi; and (2) consequently, TESARO’s shares traded at artificially inflated prices during the Class Period.

On January 12, 2018, Tesaro announced that it had updated the U.S. labeling for Varubi (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of “[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions…in the postmarketing setting, some requiring hospitalization.” The Company further stated that it “has issued a Dear Healthcare Professional (DHCP) letter.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/tsro or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Tesaro, you have until March 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 490448

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Yelp, Inc. (“Yelp” or the “Company”) (NYSE: YELP) and certain of its officers, on behalf of shareholders who purchased Yelp securities during the period between February 10, 2017 and May 9, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/yelp.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) the retention rates for existing customers, as well as revenues and growth rates for Yelp’s new customers; and (2) Yelp CEO Jeremy Stoppelman personally benefited from withholding such information by selling over $25,000,000 worth of Yelp shares (approximately 20% of his Yelp holdings) while allegedly in possession of material nonpublic information regarding Yelp’s poor financial results.

On May 9, 2017, Yelp revealed their first quarter 2017 financial results. While Yelp’s 2017 first quarter revenue and adjusted EBITDA met the its projections, Yelp was revising its 2017 Full Year guidance to reflect its poor retention rates with existing customers. Following this news, Yelp’s stock closed at $34.70 per share on May 9, 2017 and on May 10, 2017 closed at $28.33 per share.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/yelp or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Yelp you have until March 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 490446

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AMC Entertainment Holdings, Inc. (“AMC” or the “Company”) (NYSE: AMC) and certain of its officers, on behalf of shareholders who purchased AMC Class A common shares during the period between December 20, 2016 and August 1, 2017, inclusive (the “Class Period”), including purchasers in the Company’s secondary public offering on or about February 8, 2017 (the “SPO”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/amc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 and/or the Securities Act of 1933.

The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose adverse facts regarding the Company’s business and prospects in its Registration Statement and Prospectus regarding Carmike’s revenue growth and omitted material facts and included materially inaccurate statements associated with AMC’s newly acquired international business. Specifically, the complaint alleges that defendants failed to disclose that: (1) Carmike’s operations had been experiencing a prolonged period of financial underperformance due to a protracted period of underinvestment in its theaters; (2) Carmike had experienced a significant loss in market share when its loyal patrons migrated to competitors that had renovated and upgraded their theaters; (3) AMC was able to retain only a very small number of Carmike’s loyalty program members after the Carmike acquisition; (4) these issues were then having a material adverse effect on Carmike’s operations and theater attendance; and (5) as a result of defendants’ false statements and/or omissions, the price of AMC common shares was artificially inflated during the Class Period, trading above $35 per share.

On August 1, 2017, after market hours, AMC announced its preliminary second quarter 2017 financial results, revealing that it estimated to report total second quarter revenues of about $1.2 billion and a net loss of about $178.5 to $174.5 million, or a loss of $1.36 to $1.34 per diluted share. AMC also said that its 2017 revenues were expected to range between $5.10 and $5.23 billion and its 2017 net loss between $150 and $125 million, or a loss of $1.17 to $0.97 per diluted share. As a result of these disappointing figures, AMC stock dropped roughly 27% to close at $15.20 per share on August 2, 2017, or more than 50% below the price at which the shares were sold in the SPO.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/amc, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in AMC, you have until March 13, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 490444

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of Georgia on behalf of investors who purchased Aflac Incorporated (“Aflac”) (NYSE: AFL) securities between February 27, 2013 and January 11, 2018.

Click here to learn about the case: http://www.wongesq.com/pslra-c/aflac-incorporated?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Aflac hired its sales associates under false promises of high compensation packages and work-life-balance; (ii) Aflac misclassified its employees as independent contractors to reduce costs associated with unemployment insurance taxes and employment benefits; (iii) Aflac manipulated its average weekly producer equivalent metric to fabricate growth; (iv) consequently, Aflac violated its Code of Conduct and corporate social responsibility standards, and (v) as a result of the foregoing, Aflac’s public statements were materially false and misleading at all relevant times.

If you suffered a loss in Aflac, you have until April 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/aflac-incorporated?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 491208

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ) and certain of its officers, on behalf of shareholders who purchased J&J securities during the period between February 22, 2013 and February 7, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/jnj.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) J&J has known for decades that its talc products include asbestos fibers and that the exposure to those fibers can cause ovarian cancer and mesothelioma; and (2) consequently, defendants’ statements about J&J’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On February 5, 2018, CNBC reported that “court proceedings could expose potentially damaging documents” in connection with J&J’s talc products, such as Johnson’s Baby Powder. Following this news, J&J stock dropped $7.29 per share or over 5% to close at $130.39 per share on February 5, 2018. Then, on February 7, 2018, the Beasley Allen Law Firm published a press release stating that “[l]awsuits filed by ovarian cancer and mesothelioma victims are revealing never-before-seen documents from Johnson & Johnson and talc supplier, Imerys, that shed light on just how prevalent asbestos and heavy metals are in the talc used in Baby Powder.” The release continued that “[i]nternal Johnson & Johnson documents from 1972 note that asbestos was found in 100 percent of talc samples tested at the time, but this information was never released publicly,” and continued to explain how J&J stopped testing talc samples for asbestos contamination after majority of the sample batches were found to be positive for asbestos. Following this news, J&J stock dropped.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/jnj, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in J&J, you have until April 9, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484
info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 490202

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against LJM Funds Management Ltd. (“LJMIX” or the “Company”) (NASDAQ: LJMIX) and certain of its officers, on behalf of shareholders who purchased LJM Preservation and Growth Fund Class I (“LJMIX”) (MUTF: LJMIX) between February 28, 2015 and February 7, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ljmix.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) LJMIX was not focused on capital preservation and left investors exposed to an unacceptably high risk of catastrophic losses; and (2) LJMIX had not taken appropriate steps to preserve capital in down markets.

On February 5, 2018, the S&P dropped about 4.6% and LJMIX dropped roughly 80% from a previous close price of $9.82 per share on February 2, 2018, to $1.94 per share on February 7, 2018.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/ljmix, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in LJMIX, you have until April 10, 2018, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484
info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 490201

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) and certain of its officers, on behalf of shareholders who purchased Bristol-Myers securities during the period between January 27, 2015 and October 9, 2016, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/bmy.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) that Bristol-Myers’ CheckMate-026 trial was more likely to fail than Defendants were representing; (2) that Bristol- Myers’ CheckMate-026 trial failed more severely than the Company indicated it did in the Company’s August 5, 2016 announcements and disclosures; and (3) that, as a result of the foregoing, Defendants’ statements about Bristol-Myers’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

On August 5, 2016, Bristol-Myers revealed that its CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed for not meeting its primary endpoint of progression-free survival. Following this news, Bristol-Myers stock dropped $12.04 per share, or 16%, to close at $63.28 per share on August 5, 2016. The stock price continued to drop and closed at $60.30 per share on August 8, 2016. Then on October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy’s 13.2 months. Following this news, Bristol-Myers stock dropped $5.62 per share, or over 10%, to close at $49.81 per share on October 10, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/bmy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Bristol-Myers, you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484
info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 490200